Prostate-Specific Antigen Kinetics Effects on Outcomes of Low-Volume Metastatic Prostate Cancer Patients Receiving Androgen Deprivation Therapy

Table 3

PSA kinetics after ADT in LVD.

	CRPC (143, 48.3%)	Non-CRPC (153, 51.7%)
TTN, month, median (IQR)	8.7 (5.4–14.1)	16.7 (8.7–26.6)	<0.0001
Nadir PSA level, ng/ml, median (IQR)	0.75 (0.12–2.92)	0.04 (0.01–0.41)	0.618
3-month PSARR, %, median (IQR)	95.64 (87.67–98.54)	97.18 (92.65–99.16)	0.214
TFNTC, month, median (IQR)	4.3 (2.7–11.65)	15.6 (4–41.1)	<0.0001
PSADT, month, median (IQR)	3.65 (1.9–6.875)	3.4 (1.95–7.325)	0.534

CRPC: castration-resistant prostate cancer, TTN: time to PSA nadir, 3-month PSARR: 3-month PSA reduction rate, TFNTC: time from PSA nadir to CRPC, and PSADT: PSA doubling time.